Logo for Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Investor Relations Material

Latest events

Logo for Vanda Pharmaceuticals Inc

Q4 2024

Vanda Pharmaceuticals
Logo for Vanda Pharmaceuticals

Q4 2024

13 Feb, 2025
Logo for Vanda Pharmaceuticals

Q3 2024

6 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Vanda Pharmaceuticals Inc

Access all reports
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ (tasimelteon) for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone) for the treatment of bipolar disorder. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder and smith-magenis syndrome; Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness; Fanapt oral tablets for the treatment of schizophrenia; Novel fixed dose combination products: anoro progesterone vaginal system/norethindrone acetate tablets in women